D3900
地昔帕明 盐酸盐
≥98% (TLC), powder, imipramine metabolite
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H22N2 · HCl
化学文摘社编号:
分子量:
302.84
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352116
EC Number:
200-373-1
MDL number:
产品名称
地昔帕明 盐酸盐, ≥98% (TLC), powder
InChI key
XAEWZDYWZHIUCT-UHFFFAOYSA-N
InChI
1S/C18H22N2.ClH/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20;/h2-5,7-10,19H,6,11-14H2,1H3;1H
SMILES string
Cl[H].CNCCCN1c2ccccc2CCc3ccccc13
assay
≥98% (TLC)
form
powder
color
white to off-white
solubility
H2O: 50 mg/mL
originator
Sanofi Aventis
storage temp.
2-8°C
Quality Level
Gene Information
human ... SLC6A2(6530)
正在寻找类似产品? 访问 产品对比指南
Application
盐酸地昔帕明已被用于：
- 防止去甲肾上腺素神经元变性并最大程度提高DA神经元的摄取
- 防止去甲肾上腺素能系统的非选择性损坏
- 作为去甲肾上腺素再摄取抑制剂治疗大鼠病变
Biochem/physiol Actions
三环类抗抑郁药是一种比血清素转运蛋白（Ki= 61 nM）更有效的去甲肾上腺素转运蛋白抑制剂（Ki= 4 nM）。
地昔帕明可用于治疗抑郁症。。它还可用于控制儿童遗尿症。地昔帕明有助于消除糖尿病性神经病变引起的疼痛。
Disclaimer
吸湿
Features and Benefits
该化合物收录于 受体分类和信号转导手册的《生物胺转运体 》页面。想要浏览手册的其他页面， 请单击此处。
该化合物由Sanofi Aventis开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
General description
地昔帕明是丙咪嗪和洛非帕明的代谢物，它是一种有效的三环抗抑郁药。
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy
Max M B, et al.
The New England Journal of Medicine, 326(19), 1250-1256 (1992)
Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease
Tillerson J L, et al.
Neuroscience, 119(3), 899-911 (2003)
Resonant antidromic cortical circuit activation as a consequence of high-frequency subthalamic deep-brain stimulation
Li S, et al.
Journal of Neurophysiology (2007)
Desipramine
reference module in biomedical sciences (2018)
Ernest Dallé et al.
Oxidative medicine and cellular longevity, 2020, 1941480-1941480 (2020-04-11)
Nonmotor symptoms (NMS) such as anxiety, depression, and cognitive deficits are frequently observed in Parkinson's disease (PD) and precede the onset of motor symptoms by years. We have recently explored the short-term effects of Fluvoxamine, a selective serotonin reuptake inhibitor
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持